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Abstract
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and
rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without
deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6
cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1–45.8). Investigator-
assessed median progression-free survival (PFS) was not reached for ibrutinib+BR, versus 14.3 months for placebo+BR
(hazard ratio [HR] [95% CI], 0.206 [0.159–0.265]; P < 0.0001); 36-month PFS rates were 68.0% versus 13.9%, respectively.
The results are consistent with the primary analysis findings (HR= 0.203, as assessed by independent review committee,
with 17-month median follow-up). Median overall survival was not reached in either arm; HR (95% CI) for ibrutinib+BR
versus placebo: 0.652 (0.454–0.935; P= 0.019). Minimal residual disease (MRD)-negative response rates were 26.3% for
ibrutinib+BR and 6.2% for placebo+BR (P < 0.0001). Incidence of treatment-emergent adverse events (including grades 3–
4) were generally consistent with the initial HELIOS report. These long-term data support improved survival outcomes and
deepening responses with ibrutinib+BR compared with BR in relapsed CLL/SLL.
Introduction
Ibrutinib is an oral, once-daily inhibitor of Bruton’s tyrosine
kinase, an essential enzyme in the B cell receptor signaling
pathway [1–3]. The efficacy and safety of ibrutinib has been
demonstrated in patients with chronic lymphocytic leuke-
mia (CLL) and small lymphocytic lymphoma (SLL) in
treatment-naive and relapsed/refractory settings [4, 5],
leading to approvals for these indications [6, 7]. Ibrutinib as
a single agent for previously treated patients with CLL/SLL
was evaluated in a phase 1b/2 study (Study 1102 and its
extension, Study 1103) and the phase 3 RESONATE study
of ibrutinib versus ofatumumab [8, 9]. Long-term follow-up
data from these studies showed that continuing ibrutinib
treatment leads to durable and deepening responses. The
phase 1b/2 study (101 patients with previously treated CLL)
reported an overall response rate (ORR) of 89% with 10%
complete responses (CRs) and a median progression-free
survival (PFS) of 52 months after 5-year follow-up, while
the median overall survival (OS) remained unreached [9]. In
the RESONATE™ study (195 previously treated CLL
patients), the ORR was 91% (with 9% CR/CRi [CR with
incomplete bone marrow recovery]) at a median follow-up
of 44 months versus 83% (2% CR/CRi) after median
follow-up of 9.4 months [8].
Chemoimmunotherapy regimens such as bendamustine
and rituximab (BR) or fludarabine, cyclophosphamide, and
rituximab (FCR) are efficacious in patients with relapsed/
refractory CLL, but their use is often limited by patient
tolerability [10]. BR has been commonly used [11], largely
based on a phase 2 study in relapsed/refractory CLL that
showed an ORR of 59%, with 9% of patients achieving a
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CR, and a median PFS and OS of 15 and 34 months,
respectively [12]. The BR regimen formed the backbone of
the phase 1b study that led to the development of the
HELIOS study [13]. In this phase 1b study (Study 1108)
with 30 previously treated patients receiving up to six
cycles of BR+continuous ibrutinib, the CR rate was 17%
after a median of 15.8 months of follow-up, increasing to
40% at a median follow-up of 37.3 months [13].
In the phase 3 HELIOS trial of 578 patients with
relapsed/refractory CLL, ibrutinib+BR (≤6 cycles) sig-
nificantly improved PFS at the initial analysis (median
follow-up 17 months); median PFS was not reached in the
ibrutinib arm versus 13.3 months in the placebo arm (hazard
ratio [HR]= 0.203, 95% confidence interval (CI): 0.150–
0.276; P < 0.0001) [14]. The findings of HELIOS supported
the approval of ibrutinib+BR in the US and EU for patients
with relapsed/refractory CLL/SLL [6, 7].
For traditional chemoimmunotherapy, minimal residual
disease (MRD)-negative responses are prognostic for pro-
longed PFS [15] and may be a more potent predictor of PFS
than the clinical response assessment according to Interna-
tional Workshop on Chronic Lymphocytic Leukemia
(iwCLL) guidelines [16]. Because of limited long-term
follow-up data on novel targeted therapies, it is unclear
whether MRD-negative remissions are similarly prognostic
in patients receiving these agents [17]. Evaluation of MRD
status is of particular interest in ibrutinib-containing regi-
mens, as MRD negativity represents a lower disease burden
and is being investigated as a marker for treatment dis-
continuation with novel agents, which are usually admi-
nistered until progression or unacceptable toxicity. HELIOS
was the first study to evaluate MRD status in ibrutinib-
treated patients. At 17-month median follow-up, the pro-
portion of patients that achieved MRD negativity was
higher with ibrutinib+BR versus placebo+BR (13% versus
5%; P= 0.0011) [14].
As ibrutinib is a continuously administered oral once-
daily therapy, data addressing the safety profile of ibrutinib
over time, longer-term outcomes, and efficacy in patient
subgroups become increasingly relevant. We report updated
data from HELIOS (3-year follow-up) to determine survival
outcomes, evolution of responses, and durability of remis-
sions across patient subgroups, as well as long-term safety.
Subjects and methods
Study design and patients
Study design and participants have been previously
described [14]. Briefly, HELIOS (Clinicaltrials.gov
#NCT01611090) is a phase 3, randomized, placebo-
controlled, double-blind study of 578 patients conducted at
133 sites in 21 countries between September 19, 2012 and
January 21, 2014. Eligible patients were aged ≥18 years,
had a diagnosis of CLL/SLL according iwCLL criteria [18],
relapsed/refractory disease following ≥1 previous lines of
systemic therapy, an Eastern Cooperative Oncology Group
performance status of 0–1, measurable lymph node disease
(>1.5 cm) by computed tomography (CT) scan, and ade-
quate liver and kidney function. Patients with deletion 17p
(≥20% of blood or bone marrow cells examined by fluor-
escence in situ hybridization) were excluded owing to
known poor response to BR.
Patients were randomly assigned 1:1 to ibrutinib (420 mg
daily)+BR or placebo+BR. BR was administered for up to
six cycles (bendamustine: 70 mg/m2 intravenously on days
2–3 in cycle 1 and days 1–2 in cycles 2–6; rituximab: 375
mg/m2 on day 1 of cycle 1 and 500 mg/m2 on day 1 of
cycles 2–6). After 6 months of BR with ibrutinib or placebo
therapy, patients continued ibrutinib treatment or placebo
alone until disease progression or unacceptable toxicity.
Following the pre-specified interim analysis, the study was
unblinded and placebo treatment was discontinued. Subse-
quently, adverse events (AEs) were collected only for
patients continuing on ibrutinib, although patients originally
treated with placebo were followed with regular disease
evaluations and were able to crossover to ibrutinib at the
time of progression and meeting iwCLL criteria for
treatment.
End points and assessments
The primary end point was Independent Review Committee
(IRC)-assessed PFS, for which results were reported pre-
viously [14]. Investigator-assessed end points were used for
the follow-up analyses reported here. Key secondary end
points were investigator-assessed PFS, OS, and response
rates; proportion of patients with MRD-negative responses
(<1 CLL cell per 10,000 leukocytes or <0.01%) confirmed
by central laboratory assessment of peripheral blood or bone
marrow aspirate; and safety. PFS2 (time interval from ran-
domization to disease progression on next-line treatment or
death or start of next antineoplastic therapy if no pro-
gressive disease [PD] was recorded) was also assessed.
Assessment of tumor response was conducted in accor-
dance with iwCLL 2008 criteria [18]. Prior to the interim
analysis, CT scans were performed at baseline, then every
12 weeks for 2 years and every 6 months thereafter. Fol-
lowing the interim analysis, disease evaluations based on
the discretion of investigators continued every 3 months in
both arms; for patients randomized into the ibrutinib arm
who had not yet progressed, CT scans continued every
6 months until progression. Analysis of MRD was initially
performed on bone marrow sampled at the time of radi-
ological documentation of CR, with subsequent analyses of
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peripheral blood every 12 weeks. After the interim analysis,
the protocol was amended to include MRD analysis for all
patients with a partial response (PR) or better. Testing was
performed at a central laboratory by flow cytometry using
an eight-color panel of antibodies in keeping with the
EuroFlow panel [19].
Statistical analysis
Statistical analyses have been described previously [14].
Approximately 580 patients were randomized to observe
342 PFS events to detect an HR of 0.7 for the ibrutinib+BR
group relative to the placebo+BR group with 90% power at
a one-sided significance level of 0.025, using a group
sequential testing design. The distribution of time-to-event
end points was estimated using the Kaplan–Meier method.
The analysis of PFS and OS using the long-term follow-
up data was similar to those used for the primary analyses,
except that investigator assessments were used for follow-
up data. For patients in the placebo+BR group who crossed
over to receive ibrutinib, no adjustment was made for OS
analysis, i.e., the OS is defined as the time interval from
randomization to death irrespective of cause. For surviving
patients, the OS is censored at the last date known to be
alive. Separate analyses of OS corrected for crossover were
performed using the inverse probability of censoring
weighting and the rank preserving structural failure time
methods (Supplementary Figure S1). The MRD-negative
response rate was compared between treatment arms using
Fisher’s exact test; MRD assessments continued until
crossover for the placebo+BR arm.
Results
Study population
The data represent outcomes of 6 months of combination
therapy (ibrutinib+BR or placebo+BR) followed by >2
years of continuous ibrutinib or placebo treatment. For
consistency with the initial analysis, the treatment arms are
referred to as ibrutinib+BR and placebo+BR. The median
follow-up period at this analysis was 34.8 months (range:
0.1–45.8), with a median treatment duration of 34.7 months
(range: 0.2–43.3) for ibrutinib+BR and 14.3 months (range:
0.2–30.6) months for placebo+BR (Supplementary
Table S1). Sixty-six percent (188/287) of ibrutinib-treated
patients remained on treatment for ≥24 months.
Patient disposition is shown in Table 1. A total of 160
(55.4%) patients who had confirmed PD in the placebo+BR
arm crossed over to ibrutinib. At the time of this analysis,
patients received crossover therapy for a median of
16.9 months (range: 0.2–26.3). Patient demographics and
baseline characteristics data were previously reported and
were balanced between arms (Supplementary table S2) [14].
Efficacy
Investigator-assessed PFS was significantly longer with
ibrutinib+BR (not reached versus 14.3 months for placebo
+BR [HR (95% CI), 0.206 (0.159–0.265); P < 0.0001])
(Fig. 1a), and the 36-month PFS rate was 68.0% versus
13.9%, respectively. Median OS was not reached in either
arm but was significantly longer for the ibrutinib+BR arm
(HR [95% CI], 0.652 [0.454–0.935]; P= 0.019) (Fig. 1b);
the 36-month OS rate for each arm was 81.6% versus
72.9%, respectively. An analysis of OS that corrected for
crossover from the placebo+BR arm to ibrutinib+BR
confirmed the OS advantage of ibrutinib+BR (Supple-
mentary Figure S1).
In assessed subgroups, including bulky disease, chro-
mosomal deletions, ZAP70 elevation, and immunoglobulin
heavy-chain variable region (IGHV) mutation status, PFS
outcomes favored ibrutinib+BR over placebo+BR (Fig. 2a,
Supplementary Figure S3). PFS at 36 months was sig-
nificantly longer in ibrutinib-treated patients, whether they
had one or multiple lines of therapy (Fig. 2b). For patients
who had one prior therapy, 36-month PFS was 70.2% in the
ibrutinib+BR arm (95% CI: 61.3–77.5) and 15.5% in the
placebo+BR arm (95% CI: 8.3–24.7; P < 0.0001); for
patients who had ≥2 prior therapies, 36-month PFS was
65.9% for ibrutinib+BR (95% CI: 56.8–73.5) and 11.2%
with placebo+BR (95% CI: 6.5–17.4; P < 0.0001).
Median PFS2 was not reached in either arm but was
significantly longer for patients assigned to ibrutinib+BR
versus placebo+BR (HR [95% CI], 0.627 [0.445–0.881];
P= 0.0067) (Supplementary Figure S2). Among 27 patients
who discontinued ibrutinib+BR due to disease progression,
10 patients died (7 patients died due to PD, 2 due to AEs
[pneumonia and cardiac arrest] and 1 of unknown causes
following administration of subsequent CLL therapy). Eight
patients received subsequent systemic CLL therapies, four
in combination with rituximab.
The investigator-assessed ORR was 87.2% for ibrutinib
+BR and 66.4% for placebo+BR (P < 0.0001). CR/CRi
rates were 38.1% versus 8.0% (Fig. 3a), which showed
continued improvement over time versus the investigator-
assessed CR/CRi rates of 21.4% and 5.9%, respectively, in
the initial analysis [14]. Overall, 211 patients in the ibrutinib
+BR arm and 76 patients in the placebo+BR arm were
evaluated for MRD; MRD-negative response rates in per-
ipheral blood or bone marrow combined for the intent-to-
treat population were 26.3% (76/289) for ibrutinib+BR and
6.2% (18/289) for placebo+BR (P < 0.0001) (Fig. 3b). The
majority of patients (67.1%) in the ibrutinib+BR arm who
achieved MRD negativity had a CR/CRi as their best
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response; 32.9% patients had a PR as their best response. Of
these MRD-negative patients in the ibrutinib+BR arm with
PR as their best response, the CR criteria not met are listed
in Supplementary Table S3. In the placebo+BR arm, 8/18
MRD-negative patients (44.4%) had PR as their best
response. Patients who did not achieve CR/PR or who
progressed prior to MRD testing being implemented for all
responding patients had a shorter PFS (Fig. 4a, b). Among
MRD-evaluated patients, ibrutinib+BR showed a more
sustained PFS over placebo+BR at each level of MRD
(MRD-negative status <0.01%, HR [95% CI], 0.121
[0.036–0.408], P < 0.0001; MRD ≥ 0.01–<1%, HR [95%
CI], 0.153 [0.063–0.374], P < 0.0001; or MRD ≥ 1–<10%,
HR [95% CI], 0.110 [0.035–0.348], P < 0.0001) (Fig. 4a,
b). In patients receiving ibrutinib+BR, the 36-month PFS
rate for MRD-negative patients was 88.6% (95% CI: 76.8–
94.6); for those with residual disease (MRD ≥ 0.01%), it
was 60.1% (95% CI: 52.6–66.8). In the placebo+BR arm,
the 36-month PFS rate in MRD-negative patients was
54.5% (95% CI: 29.2–74.2) and 11.2% (95% CI: 7.1–16.3)
for patients with residual disease. A multivariate analysis
revealed no difference in OS according to MRD status in
responding patients.
Safety
Following the interim analysis, patients who were rando-
mized to placebo+BR stopped treatment and either crossed
over to receive next-line treatment with ibrutinib or
remained in follow-up until progression. Per protocol,
safety data were collected for 30 days after the last dose of
study medication (placebo or BR). Therefore, only safety
data for patients randomized to ibrutinib+BR are presented
(Table 2); comparison between the two treatment arms up to
the interim analysis has previously been published [14].
Treatment-emergent AEs (TEAEs) observed in >10% of
Table 1 Patient disposition
Patient status, n (%) Ibrutinib+BR
(n= 289)
Placebo+BR
(n= 289)
Total (N= 578)
Median months on study (95% CI) 35.1 (33.7–35.9) 34.5 (33.8–35.5) 34.8 (34.1–35.5)
Study treatment phase disposition, n (%)
Did not receive study drug 2 (0.7) 2 (0.7) 4 (0.7)
Ongoing 171 (59.2) 0 171 (29.6)
Discontinued study treatment 116 (40.1) 287 (99.3) 403 (69.7)
Primary reason for discontinuationa
Adverse event 47 (16.3) 34 (11.8) 81 (14.0)
Death 14 (4.8) 9 (3.1) 23 (4.0)
Lost to follow-up 1 (0.3) 1 (0.3) 2 (0.3)
Progressive disease or relapse 27 (9.3) 148 (51.2) 175 (30.3)
Investigator or sponsor decision 9 (3.1) 83 (28.7) 92 (15.9)
Withdrawal of consent 20 (6.9) 14 (4.8) 34 (5.9)
Follow-up phase disposition, n (%)
In follow-up phase 46 (15.9) 194 (67.1) 240 (41.5)
Post-treatment, prior to follow-up visitb,c 4 (1.4) 1 (0.3) 5 (0.9)
Pre-progressive disease follow-up 14 (4.8) 47 (16.3) 61 (10.6)
Post-progressive disease follow-up 28 (9.7) 146 (50.5) 174 (30.1)
Crossover to ibrutinibc 160 (55.4)
Death during crossover period 23 (8.0)
Discontinued study 72 (24.9) 95 (32.9) 167 (28.9)
Primary reason for discontinuation
Withdrawal of consent 16 (5.5) 21 (7.3) 37 (6.4)
Lost to follow-up 5 (1.7) 2 (0.7) 7 (1.2)
Death 51 (17.6) 72 (24.9) 123 (21.3)
BR bendamustine and rituximab, CI confidence interval
aIncludes patients who did not receive study medication
bA patient is counted here if the patient discontinued treatment but did not discontinue the study and did not
yet have a first follow-up visit at the time of clinical cutoff
cCrossover patients may also be counted under the “post-treatment, prior to follow-up visit” category
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patients, and their prevalence over time, are listed in
Table 3. The prevalence of TEAEs decreased over time
after year 1, except for muscle spasms and hypertension,
which remained stable (Table 3).The proportion of patients
with all-grade AEs in the ibrutinib+BR arm was 98.3%,
with 78.7% of patients reporting grade 3 or 4 events. Grade
≥3 AEs reported in ≥2% of patients are presented in Sup-
plementary Table S4; the most common grade ≥3 AEs were
neutropenia (53.7%), thrombocytopenia (15.0%), pneumo-
nia (14.3%), and febrile neutropenia (12.5%), consistent
with the initial analysis [14]. Serious TEAEs (i.e., life-
threatening, requiring hospitalization, or resulting in per-
sistent/significant incapacity) occurred in 176 (61.3%)
patients in the ibrutinib+BR arm; the most common were
pneumonia (13.6%) and febrile neutropenia (10.1%). Ser-
ious atrial fibrillation (AF) or flutter was reported for 4.9%
of patients (compared with 2.8% reporting AF in the initial
analysis) [14]. There were 28 (9.8%) TEAEs leading to
death in the ibrutinib+BR arm (compared with 19 [6.6%]
reported in the initial analysis) [14], of which the most
frequent were infections; a complete list of causes are
included in Supplementary Table S5.
Overall, the incidence of AEs of interest, including
cytopenias, bleeding, and infections, reduced during the
course of the follow-up period (Table 4). Most AEs
occurred within the first 12 months, with a sharp decrease in
onset of new events after 12 months. Bleeding events (all
grades) were reported in 34.5% of patients in the ibrutinib
+BR arm (Table 4) versus 31% of patients in the initial
report [14]; most were grade 1/2 events. No new major
hemorrhage events or deaths due to bleeding or major
hemorrhage events were reported during extended follow-
up.
Ibrutinib therapy is generally well tolerated but has been
associated with AF. A detailed review of AF following
ibrutinib treatment in HELIOS and other randomized clin-
ical trials investigating ibrutinib has been recently published
[20]. During extended follow-up, 8 additional patients in the
ibrutinib+BR arm developed AF/flutter, for a total of 29
patients (10.1%). The majority of AF events (17/29) during
the entire study duration in the ibrutinib+BR arm were
grade 1/2. While dose interruption was normal in these
cases, none required dose reductions and none were fatal; 4
(1.4%) led to treatment discontinuation.
Patients randomized to placebo+BR who crossed over
to the ibrutinib+BR arm did not demonstrate any differ-
ence in type or incidence of AEs compared with patients
originally randomized to ibrutinib+BR (Supplementary
Table S6).
Discussion
The HELIOS study was conducted in patients with
relapsed/refractory CLL/SLL and is the first trial to show a
survival benefit with ibrutinib-based therapy versus a stan-
dard chemoimmunotherapy regimen, even in the context of
a crossover design. These results support the continued use
of ibrutinib, with maintenance of superior PFS and OS
versus the placebo+BR arm and an increase in ORR and
CR rates over time. It is notable that longer-term follow-up
revealed a significant improvement in survival for ibrutinib
+BR-treated patients compared with placebo+BR, despite
the possibility of crossover after progression. Additionally,
deeper responses were reported with continuous ibrutinib
therapy, with rates of investigator-assessed CR/CRi and
MRD-negative response rising to 38% and 26%,
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respectively (compared with IRC-assessed rates of 21% and
13% at the primary analysis) [14]. This finding is consistent
with the phase 1b study 1108 of ibrutinib+BR, in which CR
rates increased from 17% to 40% with 15.7–35.4 months of
follow-up, respectively [13].
Among those tested for MRD, patients in the ibrutinib
+BR arm demonstrated prolonged PFS compared with
those in the placebo+BR arm at the same MRD level.
Caution is warranted in interpreting the MRD analyses due
to the relatively small numbers of MRD-tested patients in
the placebo+BR arm and the potential that longer-term
follow-up will be required to fully understand the prog-
nostic significance of specific MRD levels in ibrutinib+BR-
treated patients.
10
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IGHV
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Chromosome 11q
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The evolution of ORR and of CR rates following ibru-
tinib monotherapy in study 1102 for treatment-naive (ORR,
71–84%, CR 13–23%, at 22 months to 3 years of follow-up)
or previously treated (ORR, 71–90%, CR 2–7% from
26 months to 3 years of follow-up) CLL/SLL patients
demonstrates that ibrutinib is associated with durable and
deep responses as treatment continues [21]. The results
from the HELIOS study have further shown that, in patients
with relapsed/refractory disease, an induction-type period of
ibrutinib+BR therapy followed by continued ibrutinib
treatment produces better responses than BR therapy alone
and improves outcomes as the duration of therapy increases
[14]. The extended follow-up further confirmed that the
positive effects on PFS of continuing ibrutinib following
ibrutinib+BR are maintained irrespective of the number of
prior lines of therapy or the presence of poor prognostic
factors.
It remains unclear whether ibrutinib+BR provides ben-
efits beyond those observed with ibrutinib monotherapy. In
the RESONATE trial, which investigated ibrutinib
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monotherapy in patients with CLL, the 3-year PFS and OS
rates for ibrutinib were 59% and 74%, respectively. In our
study, 3-year PFS and OS rates for the ibrutinib+BR arm
were 68% and 82%, respectively. However, cross-trial
comparisons are notoriously difficult to interpret and firm
conclusions generally impossible to reach due to potential
differences in study designs and treatment populations (e.g.,
HELIOS did not enroll patients with deletion 17p); an
indirect treatment comparison of the HELIOS and RESO-
NATE trials (ibrutinib+BR versus ibrutinib arms respec-
tively) following adjustment for known confounders has
recently been published [22]. At a median follow-up of 17
and 19 months, respectively, there was no difference in
median PFS or OS, suggesting that addition of BR to
ibrutinib does not improve outcomes compared with single-
Table 3 Prevalence of most
common (≥10% of patients)
TEAEs (any grade) for ibrutinib
+BR-randomized patients
n (%) 0–1 year
(n= 287)
1–2 years
(n= 219)
2–3 years
(n= 188)
3–4 years
(n= 79)
Overall
(N= 287)
Patients with any TEAE 278 (96.9) 185 (84.5) 156 (83.0) 62 (78.5) 282 (98.3)
TEAEs reported in ≥10% of patients
Neutropenia 164 (57.1) 43 (19.6) 9 (4.8) 0 167 (58.2)
Diarrhea 98 (34.1) 39 (17.8) 21 (11.2) 7 (8.9) 110 (38.3)
Nausea 105 (36.6) 9 (4.1) 7 (3.7) 1 (1.3) 106 (36.9)
Thrombocytopenia 86 (30.0) 10 (4.6) 7 (3.7) 3 (3.8) 89 (31.0)
Anemia 64 (22.3) 5 (2.3) 5 (2.7) 1 (1.3) 68 (23.7)
Pyrexia 69 (24.0) 11 (5.0) 6 (3.2) 0 78 (27.2)
Cough 48 (16.7) 25 (11.4) 21 (11.2) 4 (5.1) 65 (22.6)
Fatigue 58 (20.2) 18 (8.2) 16 (8.5) 8 (10.1) 67 (23.3)
Pneumonia 38 (13.2) 20 (9.1) 16 (8.5) 1 (1.3) 61 (21.3)
Upper respiratory tract
infection
38 (13.2) 24 (11.0) 10 (5.3) 2 (2.5) 61 (21.3)
Bronchitis 33 (11.5) 15 (6.8) 11 (5.9) 2 (2.5) 50 (17.4)
Sinusitis 22 (7.7) 14 (6.4) 11 (5.9) 0 33 (11.5)
Nasopharyngitis 21 (7.3) 13 (5.9) 4 (2.1) 1 (1.3) 30 (10.5)
Constipation 53 (18.5) 13 (5.9) 14 (7.4) 5 (6.3) 57 (19.9)
Rash 45 (15.7) 23 (10.5) 9 (4.8) 4 (5.1) 56 (19.5)
Infusion-related reaction 48 (16.7) 0 0 0 48 (16.7)
Headache 41 (14.3) 11 (5.0) 8 (4.3) 6 (7.6) 45 (15.7)
Vomiting 40 (13.9) 3 (1.4) 2 (1.1) 0 42 (14.6)
Edema peripheral 32 (11.1) 16 (7.3) 13 (6.9) 7 (8.9) 42 (14.6)
Muscle spasms 34 (11.8) 17 (7.8) 20 (10.6) 7 (8.9) 40 (13.9)
Decreased appetite 35 (12.2) 9 (4.1) 2 (1.1) 0 38 (13.2)
Abdominal pain 30 (10.5) 8 (3.7) 7 (3.7) 2 (2.5) 37 (12.9)
Arthralgia 28 (9.8) 19 (8.7) 11 (5.9) 3 (3.8) 37 (12.9)
Febrile neutropenia 32 (11.1) 2 (0.9) 2 (1.1) 0 36 (12.5)
Back pain 29 (10.1) 8 (3.7) 10 (5.3) 3 (3.8) 36 (12.5)
Hypertension 23 (8.0) 20 (9.1) 20 (10.6) 7 (8.9) 35 (12.2)
Hyperuricemia 27 (9.4) 7 (3.2) 10 (5.3) 3 (3.8) 35 (12.2)
Chills 31 (10.8) 3 (1.4) 2 (1.1) 0 33 (11.5)
Pruritus 29 (10.1) 11 (5.0) 7 (3.7) 2 (2.5) 32 (11.1)
BR bendamustine and rituximab, TEAE treatment-emergent adverse event
Table 2 Summary of TEAEs in ibrutinib-treated patients
n (%) Ibrutinib+BR
(N= 287)
TEAEs 282 (98.3)
Grade ≥3 254 (88.5)
Drug related 246 (85.7)
Serious TEAEs 176 (61.3)
Grade ≥3 157 (54.7)
Drug related 102 (35.5)
TEAEs leading to treatment
discontinuation
46 (16.0)
TEAEs with outcome of death 28 (9.8)
BR bendamustine and rituximab, TEAE treatment-emergent adverse
event
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agent ibrutinib. An ongoing study directly comparing BR,
ibrutinib+rituximab, and ibrutinib alone in treatment-naive
CLL patients (clinicaltrials.gov NCT01886872) will pro-
vide more insights into the relative efficacy of che-
moimmunotherapy versus ibrutinib alone or with rituximab.
Importantly, the extended follow-up data supported the
manageable safety profile of ibrutinib, allowing for con-
tinued dosing following the initial induction with BR. The
pattern and incidence of AEs and TEAEs was similar to the
initial analysis when treatment extended beyond 17 months
[14] and was comparable with the safety profile reported in
other clinical trials of ibrutinib in CLL patients [5, 14, 21,
23]. Eight additional patients in the ibrutinib+BR arm
reported AF/flutter during follow-up, consistent with
reviews and meta-analyses documenting an increased risk
of developing AF in ibrutinib-treated patients versus com-
parator treatments [20, 24] and an elevated risk over time
[20]. It has previously been reported that 5–9% of CLL/SLL
patients receiving ibrutinib are affected [25]. The incidence
of bleeding events increased slightly with continued follow-
up in the ibrutinib+BR arm; however, there were no new
major hemorrhagic events or bleeding-related deaths. These
long-term follow-up data support improved survival out-
comes with ibrutinib+BR compared with BR alone in
relapsed CLL/SLL. In addition, continued ibrutinib mono-
therapy following the end of chemoimmunotherapy results
in continuing improvement in the depth of remission.
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